[HTML][HTML] Diagnosis and treatment of non-small cell lung cancer: current advances and challenges
I Diebels, PEY Van Schil - Journal of thoracic disease, 2022 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2022; 14 (6): 1753-1757|
https://dx. doi. org/10.21037/jtd-22-364 to 15% to 47.3% in the conventional chemotherapy …
https://dx. doi. org/10.21037/jtd-22-364 to 15% to 47.3% in the conventional chemotherapy …
[HTML][HTML] Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following …
X Liu, Y Zheng, S Mai, Y Tong, L Yang, M Huang… - Frontiers in …, 2022 - frontiersin.org
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) provide
dramatic response to patients with advanced EGFR-mutant non-small cell lung cancer …
dramatic response to patients with advanced EGFR-mutant non-small cell lung cancer …
[HTML][HTML] Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)
A D'Incecco, K Cannita, F Martella… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Molecular tests showed the KIF5B-RET fusion, whereas EGFR was wild type. The authors
concluded that EGFRTKI as neoadjuvant therapy is an interesting and evolving treatment …
concluded that EGFRTKI as neoadjuvant therapy is an interesting and evolving treatment …
[HTML][HTML] Critical points in the management of EGFR-mutated non-small cell lung cancer
F Casaluce, C Gridelli - Journal of Thoracic Disease, 2022 - ncbi.nlm.nih.gov
Song Y, Jia Z, Wang Y, et al. Potential treatment strategy for the rare osimertinib resistant
mutation EGFR L718Q. J Thorac Dis 2020; 12: 2771-80. Zheng Y, Zhou M, Arulananda S, et …
mutation EGFR L718Q. J Thorac Dis 2020; 12: 2771-80. Zheng Y, Zhou M, Arulananda S, et …
[HTML][HTML] Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations
K Lu, H Husain - Journal of Thoracic Disease, 2022 - ncbi.nlm.nih.gov
Wang G, Lin Y, Zheng L, et al. A new method for accurately localizing and resecting
pulmonary nodules. J Thorac Dis 2020; 12: 4973-84. Song Y, Jia Z, Wang Y, et al. Potential …
pulmonary nodules. J Thorac Dis 2020; 12: 4973-84. Song Y, Jia Z, Wang Y, et al. Potential …
[HTML][HTML] The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
EI Oduah, CS Lee, N Seetharamu - Journal of Thoracic Disease, 2022 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2022; 14 (6): 1766-1771|
https://dx. doi. org/10.21037/jtd-22-432 [hazard ratio (HR)= 0.80, 95% confidence interval …
https://dx. doi. org/10.21037/jtd-22-432 [hazard ratio (HR)= 0.80, 95% confidence interval …
[HTML][HTML] Treatment strategy of EGFR-mutated non-small cell lung cancer
F Tanaka, K Yoneda, M Takenaka… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Song Y, Jia Z, Wang Y, et al. Potential treatment strategy for the rare osimertinib resistant
mutation EGFR L718Q. J Thorac Dis 2020; 12: 2771-80. Zheng Y, Zhou M, Arulananda S, et …
mutation EGFR L718Q. J Thorac Dis 2020; 12: 2771-80. Zheng Y, Zhou M, Arulananda S, et …